@article{d846f64ed5d745338584e94dd472b86f,
title = "Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers",
abstract = " Non-manifesting carriers (NMC) of the G2019S mutation in the LRRK2 gene represent an “at risk” group for future development of Parkinson's disease (PD) and have demonstrated task related fMRI changes. However, resting-state networks have received less research focus, thus this study aimed to assess the integrity of the motor, default mode (DMN), salience (SAL), and dorsal attention (DAN) networks among this unique population by using two different connectivity measures: interregional functional connectivity analysis and Dependency network analysis (D EP NA). Machine learning classification methods were used to distinguish connectivity between the two groups of participants. Forty-four NMC and 41 non-manifesting non-carriers (NMNC) participated in this study; while no behavioral differences on standard questionnaires could be detected, NMC demonstrated lower connectivity measures in the DMN, SAL, and DAN compared to NMNC but not in the motor network. Significant correlations between NMC connectivity measures in the SAL and attention were identified. Machine learning classification separated NMC from NMNC with an accuracy rate above 0.8. Reduced integrity of non-motor networks was detected among NMC of the G2019S mutation in the LRRK2 gene prior to identifiable changes in connectivity of the motor network, indicating significant non-motor cerebral changes among populations “at risk” for future development of PD.",
keywords = "LRRK2, Parkinson's disease, graph theory network analysis, machine learning classification, resting state fMRI",
author = "Yael Jacob and Keren Rosenberg-Katz and Tanya Gurevich and Helmich, {Rick C.} and Bloem, {Bastiaan R.} and Avi Orr-Urtreger and Nir Giladi and Anat Mirelman and Talma Hendler and Avner Thaler",
note = "Funding Information: TG—Reports receiving funding for travel and speaker honoraria from the National Parkinson Foundation, Solvay pharmaceuticals, TEVA, RAFA, Medtronic, Novartis, Medison, Allergan, GlaxoSmithKline, Perrigo and Intecpharma. RCH—Reports research support from the Dutch Brain Foundation. BRB—Reports serving on the advisory board of UCB, Zambon. Serving on the editorial board of the Journal of Parkinson's Disease. Receiving grants from the NPF, MJFF, Stichting International Parkinson Fonds, Hersenstichting, ZonMw. AOU—Reports receiving research support from the Israeli Science Foundation Legacy Heritage Fund, the Chief Scientist Department of Health, Israel, the ALS Association USA and the Kahn Foundation Israel. NG—Reports serving on the advisory boards of Teva-Lundbeck, NeuroDerm, Intec Pharma and Chairing the Data monitoring safety committee of Teva LTD. Receiving funding for travel and honoraria from Teva-Lundbeck, UCB and NeuroDerm. Serving on the editorial board of the Journal of Parkinson's Disease. Being a consultant for LTI, NeuroDerm and Intec Pharma. Receiving grants from the NPF, Israeli Science Foundation, NIH, MJFF, EU FP7. AM—Reports receiving funding from the National Parkinson Foundation. TH—Reports funding from the I-CORE program and The Israel Science Foundation. AT—Reports receiving honoraria from Abbvie. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",
year = "2019",
month = jun,
day = "1",
doi = "10.1002/hbm.24543",
language = "English",
volume = "40",
pages = "2546--2555",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "8",
}